SOUTH EASTON, Mass., July 22 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (“PBI” or “the Company”) today announced an important expansion of its pressure cycling technology (“PCT”) product line with the unveiling of a new PCT consumable product, the FT500-ND PULSE Tube - a novel, single-use processing container designed specifically for the Company’s PCT Sample Preparation System (“PCT SPS”). The Company also announced the unveiling of its first three FT500-ND dependent applications. Two applications are for the extraction of biomolecules (e.g., DNA, RNA, proteins, and lipids) from bacteria and fungi in complex matrices such as soil (“Soil PrEP”) or skin cells collected on adhesive tape (“SkinTape-PrEP”). The other application is for the extraction and isolation of mitochrondria from cell suspensions (“Mitochrondria Cell-PrEP”). The single-use, variable volume FT500-ND and related PCT-dependent applications were unveiled at the 22nd Annual Symposium of The Protein Society, being held from July 19-23 in San Diego, CA.
Dr. Nathan Lawrence, Vice President of Marketing for PBI, said: “The FT500-ND is based on the field-proven FT500 PULSE Tube, the current, primary consumable of the PCT Sample Preparation System. The FT500-ND is similar to the FT500 in look and feel, except there is no lysis disk in this new PULSE Tube. This design change was based on strong market demand for a new PCT consumable for the rapid and reproducible processing of solutions and suspensions that do not require partial homogenization by passage through a lysis disk, and for a consumable that could accept smaller sample volumes. It is the result of more than a year of testing in several laboratories using various sample sizes and types. We are encouraged with the data generated to date, and believe that the new FT500-ND PULSE Tube and the three new PCT- dependent applications fill a large, growing, yet unmet need for a single-use PCT consumable that offers variable sample volumes (5x the range of the existing FT500) and lacks a lysis disk. We believe that this important addition to our PCT product line should enable us to introduce PCT to a new group of research scientists, and that it should subsequently help drive our future installed base of Barocycler instruments.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.
Forward Looking Statements
Statements contained in this press release regarding the Company’s intentions, hopes, beliefs, expectations, or predictions of the future are “forward-looking’’ statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the reported effectiveness of the new FT500-ND to extract biomolecules from bacteria and fungi in soil and skin cells, and mitochondria from cells; the variable sample volumes allowed by the FT500-ND; the implication that the Company will develop additional applications for the FT500-ND; the perceived demand for the FT500- ND PULSE Tube and the three new PCT dependent applications; and the Company’s belief that the introduction of the FT500-ND and the new PCT-dependent applications will help to drive the installed base of PCT instruments. These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of PCT; the possibility that due to the nature of the research being performed, laboratories may not find the use of the FT500-ND to be as advantageous as reported by the Company; that due to competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by scientists and laboratories; the possibility that the FT500-ND and the new PCT-dependent applications may not drive the installed base of PCT instruments; and the other risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
CONTACT: Richard T. Schumacher, President & CEO, or Edward H. Myles, Sr.
Vice President of Finance & CFO, both of Pressure BioSciences, Inc.,
+1-508-230-1828
Web site: http://www.pressurebiosciences.com/
